Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSK 4-component Strep A vaccine + alum
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
GSK's 4-component Group A Streptococcus vaccine with alum is an investigational protein-based vaccine designed to prevent infections caused by Streptococcus pyogenes (Group A Strep). The vaccine formulation consists of four synthetic peptide components targeting specific Strep A antigens, combined with aluminum hydroxide (alum) as an adjuvant to enhance the immune response. It is currently being evaluated in a Phase 1 clinical trial to assess safety, reactogenicity, and immunogenicity in healthy young adults. The vaccine aims to generate protective antibodies against the pathogen to prevent conditions ranging from pharyngitis to severe invasive diseases and post-streptococcal complications like rheumatic heart disease.
- Other names
- GSK 4-component Group A Streptococcus vaccineGSK4-component Group A Streptococcus vaccineGSK-4-component Group A Streptococcus vaccineGSK 4-component Strep A vaccine with alum adjuvantGSK4-component Strep A vaccine with alum adjuvantGSK-4-component Strep A vaccine with alum adjuvantGSK 4-component Vaccine Against Group A Streptococcus Pyogenes (Strep A) With Alum
Beyond the preview
Go deeper on GSK 4-component Strep A vaccine + alum.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSK 4-component Strep A vaccine + alum.